A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

Engraftment reached 100% for some microbial species known to support overall gut health and protect against graft-versus-host disease ... such as less acute GVHD, fewer hospitalizations, fewer ...

Shernan Holtan, MD, has been named the recipient of 2025 Lukas D. Wartman Award. Holtan, chief of blood and marrow ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Please provide your email address to receive an email when new articles are posted on . Impairment of social life was listed as an ongoing quality-of-life impact for every patient. Psychological ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the ...

Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Mesoblast (MESO) to $24 from $15 and keeps an Overweight rating on the ...